Kronos Bio, Inc. (KRON)
NASDAQ: KRON · Real-Time Price · USD
0.860
+0.010 (1.18%)
Nov 20, 2024, 4:00 PM EST - Market closed
Kronos Bio Revenue
Kronos Bio had revenue of $2.37M in the quarter ending September 30, 2024, with 158.45% growth. This brings the company's revenue in the last twelve months to $9.87M, up 146.56% year-over-year. In the year 2023, Kronos Bio had annual revenue of $6.29M.
Revenue (ttm)
$9.87M
Revenue Growth
+146.56%
P/S Ratio
5.19
Revenue / Employee
$156,571
Employees
63
Market Cap
51.85M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OptiNose | 75.67M |
Precision BioSciences | 75.10M |
Apyx Medical | 48.54M |
Cytosorbents | 37.74M |
BGM Group | 29.87M |
Lucid Diagnostics | 4.19M |
vTv Therapeutics | 1.00M |
KRON News
- 6 days ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 4 weeks ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 weeks ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 6 weeks ago - Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - GlobeNewsWire
- 2 months ago - Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - GlobeNewsWire
- 2 months ago - Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - Kronos Bio Announces Participation in Medical and Investor Conferences in September - GlobeNewsWire
- 4 months ago - Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer - GlobeNewsWire